Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis.

• DOI: 10.2340/actadv.v101.1128
• Publication Date: 2022-01-31
• Authors: Roselie Achten; Chantal van Luijk; Lisa Van der Rijst; Daphne S. Bakker; Lotte S. Spekhorst; Nicolaas P. A. Zu...; Marie L. A. Schut...; Geertruida L. E. ...; Angelique N. Voor...; Marijke Kamsteeg; Inge Haeck; Marlies de Graaf; Judith L. Thijs; Joke de Boer; Marjolein de Brui...
• Keywords: Dupilumab

This study identified risk factors for the development of dupilumab-associated ocular surface disease in patients with moderate-to-severe atopic dermatitis a large prospective daily practice cohort. Data from Dutch BioDay Registry were used to assess developing disease, by performing univariate and multivariate logistic regression analyses. A total 469 included, which 152/469 (32.4%) developed disease. Multivariate analysis showed statistically significant association history any eye (history self-reported episodic acute allergic conjunctivitis excluded) combined use ophthalmic medication at start dupilumab (odds ratio 5.16, 95% confidence interval 2.30-11.56, p < 0.001). In conclusion, baseline was associated dermatitis.